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Abstract
Introduction Symptoms and functional limitation are frequently reported by survivors of acute pulmonary embolism (PE). 
However, current guidelines provide no specific recommendations on which patients should be followed after acute PE, 
when follow-up should be performed, and which tests it should include. Definition and classification of late PE sequelae are 
evolving, and their predictors remain to be determined.
Methods In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we focused on 219 survivors of 
acute intermediate-risk PE with clinical and echocardiographic follow-up 6 months after randomisation as well as over the 
long term (median, 3 years after acute PE). The primary outcome was a composite of (1) confirmed chronic thromboembolic 
pulmonary hypertension (CTEPH) or (2) ‘post-PE impairment’ (PPEI), defined by echocardiographic findings indicating an 
intermediate or high probability of pulmonary hypertension along with New York Heart Association functional class II–IV.
Results Confirmed CTEPH or PPEI occurred in 29 (13.2%) patients, (6 with CTEPH and 23 with PPEI). A history of chronic 
heart failure at baseline and incomplete or absent recovery of echocardiographic parameters at 6 months predicted CTEPH 
or PPEI at long-term follow-up.
Conclusions CTEPH or PPEI occurs in almost one out of seven patients after acute intermediate-risk PE. Six-month echo-
cardiographic follow-up may be useful for timely detection of late sequelae.
Keywords Chronic thromboembolic pulmonary hypertension · Post-PE impairment · Pulmonary embolism · Right 
ventricular dysfunction · Risk stratification
Introduction
Persisting symptoms and abnormalities of cardiorespiratory 
function or of echocardiographic parameters are frequently 
reported or detected after acute pulmonary embolism (PE). 
They may be accompanied by reduced exercise capacity, 
impaired quality of life, and overall perception of a health 
status which is ‘worse than before the acute PE event’ [1–7]. 
The frequent clinical need for caring for these patients is not 
met by current guidelines, which provide no specific advice 
on whom, when, and how to follow after acute PE [8].
Recently, the concept of post-PE impairment (PPEI) or 
the ‘post-PE syndrome’ was proposed, encompassing vari-
ous combinations of complaints and clinical findings as well 
as imaging, functional or haemodynamic abnormalities, at 
the far end of which stands a life-threatening obstructive vas-
culopathy, chronic thromboembolic pulmonary hypertension 
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(CTEPH) [1, 4, 9–11]. CTEPH is often diagnosed with delay 
and the identification of predictors of CTEPH after an acute 
PE may help to reduce this delay. The definition of PPEI 
continues to evolve, and it is hoped that the results of ongo-
ing studies will help to further optimise the detection, pre-
diction, and classification of late PE sequelae [10].
In patients with intermediate-risk PE included in the 
Pulmonary Embolism Thrombolysis (PEITHO) study [12], 
for whom long-term follow-up was available [13], we ana-
lysed cardiopulmonary symptoms and abnormal echocar-
diographic parameters indicating pulmonary hypertension 
or right ventricular (RV) dysfunction 6 months after acute 
PE. Our aim was to find out whether these parameters were 
associated with CTEPH or PPEI at long-term follow-up. 
We thus sought to identify predictive tools for following 
the course of a patient who has suffered acute PE, allowing 
timely detection or exclusion of late clinical and haemody-
namic sequelae.
Patients and methods
In PEITHO, a total of 1,006 patients with acute interme-
diate-risk PE were enrolled at 76 sites between November 
2007 and July 2012 and randomised to receive tenecteplase 
or placebo (in addition to standard parenteral anticoagula-
tion) [12]. Eligibility criteria included (1) an objectively 
confirmed diagnosis of acute PE with symptom onset 15 
days or less before randomisation, (2) RV dysfunction 
detected on echocardiography or spiral computed tomog-
raphy of the chest, and (3) a positive troponin I or T test 
[12]. The primary efficacy outcome was death or haemody-
namic decompensation/collapse occurring within 7 days of 
randomisation.
An extension of the follow-up period to cover 2 years or 
longer was included in the third amendment of the study 
protocol, which was signed by 28 study sites having enrolled 
a total of 709 patients [13].
For the present analysis, we focused on PE survivors 
with available echocardiographic data at 6 months and over 
long-term follow-up (2 years or longer). Complete recovery 
of echocardiographic parameters between baseline and the 
6-month visit was defined as normalisation of all echocar-
diographic parameters of RV dysfunction as documented by 
the investigators in the PEITHO case report form (Table 1). 
The New York Heart Association (NYHA) functional classi-
fication was used to provide an estimate of residual (or new) 
functional limitation during physical activity or at rest, and 
was assessed by the investigator team during a visit of the 
patient to the participating centre. The functional class prior 
to the acute PE event was not determined. The findings were 
collected in ad hoc-developed case report forms.
The outcome included a confirmed diagnosis of CTEPH 
or PPEI at long-term follow-up. The diagnostic workup for 
Table 1  Definition of echocardiographic recovery at 6 months and of post-PE impairment at long-term follow-up
CTEPH, chronic thromboembolic pulmonary hypertension; LVEDD, left ventricular end diastolic dimension; NYHA, New York Heart Associa-
tion; PE, pulmonary embolism; RVEDD, right ventricular end diastolic dimension; RV, right ventricular; sPAP, systolic pulmonary artery pres-
sure
* The definition of echocardiographic probability of pulmonary hypertension followed the criteria recommended by current European guidelines 
for standardising the follow-up assessment of patients with (chronic) pulmonary hypertension, but some of the parameters and cut-off values 
were adapted to correspond to the data collected in the case report forms of the PEITHO trial
Recovery of echocardiographic parameters between baseline and 6 months
Echocardiographic parameters
 a) sPAP > 35 mmHg (vs ≤ 35 mmHg) or tricuspid systolic velocity > 2.6 m/s (vs ≤ 2.6 m/s)
 b) RVEDD > 30 mm (vs ≤ 30 mm)
 c) RVEDD/LVEDD > 0.9 (vs ≤ 0.9)
 d) Hypokinesia of the RV free wall
Complete recovery Normalisation of all the echocardiographic parameters of right ventricu-
lar dysfunction listed above
Partial recovery Normalisation of some, but not all, echocardiographic parameters
No recovery Normalisation of none of the parameters that were elevated or abnormal 
at baseline
Combined study outcome
Confirmed diagnosis of CTEPH, or
Post-PE impairment (PPEI), defined as a combination of the following criteria [(a) and (b) both present)]:
 Intermediate/high echocardiographic probability of pulmonary hypertension,* defined as estimated sPAP > 35 mm Hg, or sPAP ≤ 35 mmHg 
associated with at least one of the following:
  RVEDD > 30 mm, or RVEDD/LVEDD > 0.9
  hypokinesia of the RV free wall
 Exertional dyspnoea of the NYHA class II, III or IV
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(suspected) CTEPH was performed at each participating 
site as part of standard medical care; it was not mandated 
by the PEITHO study protocol or its amendment concern-
ing the extension of the follow-up period [13]. As shown in 
Table 1, PPEI was defined as echocardiographic findings 
indicating an intermediate or high probability of (chronic) 
pulmonary hypertension, combined with exertional dysp-
noea of the New York Heart Association functional class 
II–IV. The definition of echocardiographic probability of 
pulmonary hypertension followed the criteria recommended 
by the current guidelines of the European Heart Association 
and European Respiratory Society [14], although some of 
the parameters and cut-off values had to be adapted to cor-
respond to the data collected in the case report forms of the 
PEITHO trial (which had been defined before the pulmonary 
hypertension guidelines). CTEPH and PPEI cases were not 
independently adjudicated.
In the descriptive analysis of the patients’ baseline char-
acteristics and study outcomes for the overall population and 
for each treatment arm separately, percentages were used for 
categorical variables, and means (standard deviation, SD) 
or medians (interquartile range, IQR) for continuous vari-
ables. We analysed the effects of thrombolysis on the pri-
mary outcome by means of a two-sided Chi-square test for 
proportions. We searched for predictors of CTEPH or PPEI 
(the dependent variable) among clinically selected (1) base-
line clinical characteristics, and (2) parameters assessed at 
6-month assessment, notably NYHA functional class and an 
incomplete or absent recovery of echocardiographic param-
eters (vs complete recovery) compared to baseline by fitting 
univariate and multivariable stepwise logistic regression 
models. Missing values of single echocardiographic param-
eters were considered normal if < 5% or total. SAS software 
9.2 was used for data analysis.
Results
Of 709 intermediate-risk patients randomised at the PEI-
THO sites which participated in the extension of the follow-
up period, 136 patients died and 13 were lost during fol-
low-up [13]. Among 560 survivors, echocardiography was 
performed in 219 patients at 6 months and over long-term 
follow-up (Fig. 1), of whom 112 were treated with tenect-
eplase and 107 with placebo. The median length of observa-
tion was 37 months (interquartile range, 27–49 months). In 
Table 2, the baseline parameters of survivors with echocar-
diographic follow-up data are compared with those without 
echocardiographic follow-up data.
At long-term follow-up, 29 of 219 (13.2%) patients were 
diagnosed with CTEPH (n = 6) or fulfilled the PPEI crite-
ria (n = 23). We did not detect any differences in the occur-
rence of CTEPH or PPEI among patients randomised to 
tenecteplase (14.3%) versus anticoagulation alone (12.1%) 
(p = 0.67).
Table 3 shows the unadjusted and adjusted estimates for 
the prediction of CTEPH or PPEI at long-term follow-up. 
Chronic heart failure, as reported by local study investiga-
tors, at baseline [adjusted odds ratio (OR) 7.72, 95% con-
fidence interval (CI) 1.28–46.65] and incomplete or absent 
recovery of echocardiographic parameters at 6 months 
[adjusted OR 7.14 (95% CI 2.15–23.78)] were identified as 
independent predictors of CTEPH or PPEI.
Discussion
We investigated the long-term clinical and haemodynamic 
course of 219 survivors of acute intermediate-risk PE pre-
senting with RV dysfunction and positive cardiac biomark-
ers, who had been enrolled in the PEITHO trial [12]. Long-
term follow-up was conducted for a median of 37 months 
after acute PE. This examination revealed the presence of 
‘post-pulmonary embolism impairment’ or CTEPH in 13.2% 
of the patients. The results of our regression analysis sug-
gest that an abnormal follow-up echocardiogram, performed 
‘early’ (6 months) after acute PE, may predict an elevated 
risk of persistent or progressive symptoms and RV dysfunc-
tion over the long term.
Our results indicate that persistence of clinical and 
haemodynamic impairment is a frequent complication after 
intermediate-risk PE and that 6-month clinical and echo-
cardiographic assessment may be a useful tool for predict-
ing these late PE sequelae. Consistent with what we had 
previously reported [13], we did not observe any impact of 
systemic thrombolysis on the risk of developing CTEPH or 
PPEI.
The definition of PPEI is still evolving; thus far, attention 
has been focused on the most severe but least frequent PE 
sequelae, CTEPH. In this regard, existing epidemiological 
data are characterised by a high degree of heterogeneity. A 
Fig. 1  Flowchart of patient inclusion for the present analysis
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systematic review and meta-analysis provided pooled esti-
mates for the 2-year rate of CTEPH after PE, ranging from 
0.6% among all comers to 3.2% in survivors of the acute 
phase [15]. Importantly, since the diagnosis and surgical 
treatment of CTEPH are delayed more than 1 year after the 
onset of symptoms [16, 17], an increased awareness for and 
early detection of persisting (or newly developing) pulmo-
nary hypertension or RV dysfunction after PE might also 
lead to a timely diagnosis and improved management of 
CTEPH.
The results of the present analysis are in agreement with 
previous reports which suggested a relatively high incidence 
of echocardiographic and functional impairment after PE. 
For example, in a prospective cohort study of 127 patients 
diagnosed with ‘submassive’ PE, 17% had RV dysfunction 
at 6 months, 17% had functional limitation, and 8% both [2]. 
In another study of 78 patients with acute PE, an estimated 
baseline systolic pulmonary artery pressure > 50 mmHg was 
associated with persistence of pulmonary hypertension and 
signs of RV dysfunction at 1 year [18]. In the INvestigating 
the role oF disease monitORing in incident PE (INFORM) 
study, 8% of 7,068 patients with a first episode of acute PE 
had a medical claim for pulmonary hypertension over a 
2-year period, but only half of the subjects with persisting 
symptoms underwent further diagnostic workup by an imag-
ing test [19]. Finally, in the prospective Evaluation of Long-
term Outcomes after Pulmonary Embolism (ELOPE) study, 
almost 50% of 86 patients had exercise limitation measured 
at cardiopulmonary exercise testing 1 year after acute PE 
[9]. Using a concept similar to that of our study, i.e. focus-
ing on the importance of early assessment to predict the 
long-term course after acute PE, the ELOPE investigators 
showed that a  VO2 peak < 80% of the predicted value on 
cardiopulmonary exercise testing, performed 1 month after 
acute PE, was significantly associated with, i.e. predicted the 
persistence of this abnormal finding at 1 year [9]. However, 
Table 2  Baseline characteristics 
of patients with versus 
those without complete 
echocardiographic assessment
IQR, interquartile range; SD, standard deviation; NYHA, New York Heart Association
Included
(n = 219)
Excluded
(n = 354)
p
Age (years), mean (SD) 64.8 (14.5) 64.6 (16.7) 0.90
Male sex, n (%) 111 (50.7) 157 (44.4) 0.14
Body weight (kg), mean, (SD) 84.0 (15.7) 83.0 (18.4) 0.50
Systolic blood pressure (mmHg), mean (SD) 133.6 (17.2) 130.5 (18.1) 0.04
Heart rate (beats/min), mean (SD) 91.3 (17.4) 93.8 (16.5) 0.08
Respiratory rate (/min), mean (SD) 21.6 (5.6) 21.4 (5.5) 0.72
Oxygen administration,  n (%) 181 (82.6) 309 (87.3) 0.13
Chronic obstructive pulmonary disease, n (%) 7 (3.2) 15 (4.2) 0.54
Chronic heart failure,  n (%) 9 (4.1) 15 (4.2) 0.92
Prior venous thromboembolism,  n (%) 51 (23.3) 98 (27.7) 0.24
Active cancer,  n (%) 8 (3.7) 16 (4.5) 0.61
Recent surgery or trauma,  n (%) 17 (7.8) 25 (7.1) 0.75
Immobilisation,  n (%) 25 (11.4) 30 (8.5) 0.27
Oestrogen use,  n (%) 14 (6.4) 27 (7.6) 0.58
Table 3  Factors associated 
with confirmed chronic 
thromboembolic pulmonary 
hypertension or post-pulmonary 
embolism impairment at long-
term follow-up
CI confidence interval, NYHA New York Heart Association, OR odds ratio
Unadjusted OR 95% CI Adjusted OR 95% CI
Age ≤ 65 years 0.36 0.15–0.89 - -
Male sex 0.47 0.21–1.08 - -
Chronic heart failure 3.81 0.89–16.89 7.72 1.28–46.65
Active cancer 4.08 0.92–18.16 - -
Prior venous thromboembolism 1.10 0.44–2.76 - -
Unprovoked pulmonary embolism 0.99 0.37–2.61 - -
Tenecteplase treatment 1.19 0.54–2.62 - -
NYHA II, III or IV (assessed at 6 months) 3.20 1.33–7.71 - -
Incomplete or absent recovery of echo 
parameters (assessed at 6 months)
4.77 1.80-12.63 7.14 2.15–23.78
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differences between the design, patient populations and out-
comes in the ELOPE study and the PEITHO trial do not 
allow a direct comparison of the results of functional and 
echocardiographic assessment.
Our study has some limitations. First, we excluded 
patients with incomplete follow-up data; however, the com-
parison of baseline characteristics and 6-month findings 
between included and excluded patients (Table 2) suggests 
that selection bias is unlikely. Second, PEITHO did not 
include cardiopulmonary exercise or laboratory biomarker 
testing at follow-up, and thus the NYHA functional clas-
sification, a less standardised parameter [20], was used as 
the sole surrogate of functional impairment, combined with 
echocardiography at rest. Regarding the latter test, it needs 
to be mentioned that baseline and follow-up echocardio-
graphic parameters were interpreted locally and not by a core 
laboratory. Third, a small overall number of patients were 
diagnosed with PPEI and particularly CTEPH, which led to 
large confidence intervals of the risk estimates limiting the 
ability to determine the strength of the association between 
the independent variables and the study outcome, and to 
adjust for important additional covariates. Finally, we can-
not exclude the possibility that some patients may already 
have had CTEPH at the time of inclusion in PEITHO [21]. 
This represents a limitation of most existing studies in the 
field, as they were not designed to systematically search for 
pre-existing CTEPH using standardised criteria. Therefore, 
our findings might partly reflect a chronic condition present 
prior to the acute PE event, including pre-existing CTEPH or 
pulmonary hypertension of other cause(s), which may have 
contributed to the identification of ‘chronic heart failure’ as 
a significant predictor of outcome.
In light of the above limitations, and to the fact that no 
standardised CTEPH diagnosis protocol was mandated 
by the PEITHO trial protocol, no firm conclusions can be 
drawn from our analysis regarding the possible efficacy of 
systemic thrombolysis for prevention of late PE sequelae. 
Moreover, neither the PEITHO trial nor the present analysis 
was designed to directly address the question on which pro-
portion of the patients with PPEI may ultimately progress 
to CTEPH, and at what rate this may happen.
In conclusion, we found that chronic thromboembolic 
pulmonary hypertension or the combination of exertional 
dyspnoea with persistent or progressing right ventricular 
dysfunction (termed post-pulmonary embolism impair-
ment) occurs in almost one out of seven patients after acute 
intermediate-risk pulmonary embolism. Our results, which 
suggest that 6-month echocardiographic follow-up may be 
useful in detecting or predicting late sequelae of pulmo-
nary embolism, must be confirmed by future, appropriately 
designed studies.
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